PD23-06 CHANGE IN SEXUAL FUNCTION IN MEN WITH LUTS/BPH ASSOCIATED WITH LONG-TERM TREATMENT WITH DOXAZOSIN, FINASTERIDE, AND COMBINED THERAPY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Hormonal Therapy1 Apr 2014PD23-06 CHANGE IN SEXUAL FUNCTION IN MEN WITH LUTS/BPH ASSOCIATED WITH LONG-TERM TREATMENT WITH DOXAZOSIN, FINASTERIDE, AND COMBINED THERAPY R. Charles Welliver, Chyng-Wen Fwu, Paul W. Eggers, Ziya Kirkali, Kevin T. McVary, Pamela K. Burrows, and John W. Kusek R. Charles WelliverR. Charles Welliver More articles by this author , Chyng-Wen FwuChyng-Wen Fwu More articles by this author , Paul W. EggersPaul W. Eggers More articles by this author , Ziya KirkaliZiya Kirkali More articles by this author , Kevin T. McVaryKevin T. McVary More articles by this author , Pamela K. BurrowsPamela K. Burrows More articles by this author , and John W. KusekJohn W. Kusek More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1843AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Comprehensive assessment of sexual function (SF) in men with LUTS treated long-term with drugs using validated instruments is lacking. We examined the effects of doxazosin, finasteride and combined therapy on SF assessed by the Brief Male Sexual Function Inventory (BMSFI) using the Medical Therapy of Prostatic Symptoms (MTOPS) data. METHODS The MTOPS study was a multi-center, randomized, double-blind, placebo-controlled clinical trial with a primary outcome of time-to-BPH progression. Change in sexual function was a secondary outcome and was assessed by the BMSFI. Men who completed the BMSFI at baseline and at least once during follow-up were able to be assessed. RESULTS 2,783 men were analyzed. Overall, men’s sexual health declined over the study period. Men taking 5ARIs experienced significant worsening of ejaculatory function compared with placebo. Men assigned to combined therapy also experienced significant worsening in erectile function and sexual problem assessment. In contrast, there was no significant difference in changes in any of the BMSFI domains when men assigned to doxazosin were compared to those on placebo. Libido changes were not different between groups. CONCLUSIONS Our results differ from most other reports of sexual function with LUTS treatment as all domains of function were serially measured prospectively and for the duration of observation. Treatment with doxazosin alone had minimal, if any, negative impact on sexual function in men with LUTS, while treatment with 5ARIs was associated with a worsening of several domains of sexual function. Physicians should discuss the possible long-term negative effects of drug treatment for LUTS on sexual function with their patients to better inform their decision-making on treatment. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e668 Advertisement Copyright & Permissions© 2014MetricsAuthor Information R. Charles Welliver More articles by this author Chyng-Wen Fwu More articles by this author Paul W. Eggers More articles by this author Ziya Kirkali More articles by this author Kevin T. McVary More articles by this author Pamela K. Burrows More articles by this author John W. Kusek More articles by this author Expand All Advertisement Advertisement Loading ...